Skip to content

Trial Summary

This study is testing a new cancer treatment, atezolizumab, given in combination with standard chemotherapy (paclitaxel and carboplatin) for endometrial cancer.

Acronym:

AtTEND

ACTRN/NCT /ethics:

ACTRN12619000900112

Scientific title:

Phase III Double-Blind Randomized Placebo Controlled Trial of Atezolizumab in Combination with Paclitaxel and Carboplatin in Women with Advanced/Recurrent Endometrial Cancer.

Sponsor / Cooperative group:

NHMRC/MaNGO

Trial & Patient Characteristics

Cancer TypeGynaecological
Trial TypeTreatment
PhasePhase III
Age Range18 years and older
SexFemale
Tumour Stream Enometrial
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2019-10-01
Anticipated End Date2022-07-31

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Emailanne.milton@sa.gov.au
Phone08 7074 2342
Principal InvestigatorDr Sid Selva
Recruitment StatusRecruiting